Shopping Cart

Your shopping cart is currently empty

Ancriviroc

Name: Ancriviroc
Brand: TargetMol
SKU: T30047
Price: 195 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T30047Cas No. 370893-06-4

Alias Schering C, SCH-351125, CHEMBL336672, AC1NUILE, [3H]ancriviroc

Ancriviroc (SCH-351125) is an oxime-piperidine compound with strong antiretroviral activity and an orally bioavailable small molecule chemokine receptor CCR5 antagonist (Kd value 9.27nM) that enters HIV-1 through the CCR5 co-receptor and is used to study HIV-1.

Ancriviroc

Copy Product Info

😃Good

Purity: 99.82%

Catalog No. T30047Alias Schering C, SCH-351125, CHEMBL336672, AC1NUILE, [3H]ancrivirocCas No. 370893-06-4

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$195	In Stock	In Stock
5 mg	$483	In Stock	In Stock
10 mg	$692	In Stock	In Stock
25 mg	$1,080	In Stock	In Stock
50 mg	$1,490	In Stock	In Stock
100 mg	$1,970	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.82%

Appearance:Solid

Color:White to Yellow

Resource Download

COA HNMR HPLC

Product Introduction

Ancriviroc AI Summary

Ancriviroc exhibits a range of bioactivities, including the inhibition of RANTES binding to the C-C chemokine receptor type 5 (CCR5) with a Ki value of 2.1 nM and inhibition of HIV-1 reporter virus (ADA) entry into U-87 cells with an IC50 of 0.6 nM. Additionally, it shows potent activity against various clinical isolates of HIV-1 in PBMC cultures, with IC90 values ranging from 10.0 nM to 400.0 nM. Pharmacokinetic studies reveal moderate to high absorption and plasma clearance rates following intravenous administration, along with relatively short half-lives. After oral administration, the compound demonstrates fast Tmax values, varying Cmax and AUC values, and different percentages of bioavailability, with 63.0% in rats, 52.0% in monkeys, and 92.0% in dogs at a dose of 10 mg/kg. Ancriviroc has a LogD7.4 value of 2.14, indicating its distribution coefficient in an octan-1-ol/water system at pH 7.4. Furthermore, it exhibits binding affinity to the CXCR4-Y251A mutant with an IC50 of 16.0 nM..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ancriviroc (SCH-351125) is an oxime-piperidine compound with strong antiretroviral activity and an orally bioavailable small molecule chemokine receptor CCR5 antagonist (Kd value 9.27nM) that enters HIV-1 through the CCR5 co-receptor and is used to study HIV-1.
In vitro	METHODS: Chinese hamster ovary (CHO) cell membranes expressing human CCR5 were incubated with Ancriviroc (SCH-351125) (10-0.3 nM), and Ki values were calculated using GRAPHPAD PRISM software based on experimentally determined IC50 and KD values. RESULTS Ancriviroc (SCH-351125) inhibited the binding of RANTES to CHO cell membranes expressing human CCR5 in a dose-dependent manner with a Ki value of 2.9 nM; Ancriviroc (SCH-351125) bound to CCR5 with high affinity with a KD of 9.27 nM. [1]
In vivo	METHODS: In a SCID-mouse model treated with (SCH-351125) (30 mg/kg, orally, daily), HLA-ABC levels on implanted cells from treated and untreated mice were measured by FACS analysis using mAb W6/32. RESULTS SCH-C had potent and dose-dependent antiviral activity in the SCID-mouse model; MHC class I expression on implanted cells from (SCH-351125)-treated mice was reduced in a dose-dependent manner, further confirming the inhibition of viral replication by SCH-C. [1]
Synonyms	Schering C, SCH-351125, CHEMBL336672, AC1NUILE, [3H]ancriviroc

Chemical Properties

Molecular Weight	557.533
Formula	C₂₈H₃₇BrN₄O₃
Cas No.	370893-06-4
Smiles	CCO\N=C(\C1CCN(CC1)C1(C)CCN(CC1)C(=O)c1c(C)ccn(=O)c1C)c1ccc(Br)cc1
Relative Density.	1.32 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (89.68 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.7936 mL	8.9681 mL	17.9362 mL	89.6808 mL
5 mM	0.3587 mL	1.7936 mL	3.5872 mL	17.9362 mL
10 mM	0.1794 mL	0.8968 mL	1.7936 mL	8.9681 mL
20 mM	0.0897 mL	0.4484 mL	0.8968 mL	4.4840 mL
50 mM	0.0359 mL	0.1794 mL	0.3587 mL	1.7936 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc